To ask the Secretary of State for Health and Social Care, what recent discussions she has had with people with (a) cystic fibrosis and (b) representative organisations on the draft guidance on the future availability of (i) Orkambi, (ii) Symkevi and (iii) Kaftrio on the NHS.
Answered on
30 November 2023
The National Institute for Health and Care Excellence (NICE) is an independent body and is responsible for leading engagement with interested parties in the development of its recommendations on medicines. NICE has recently consulted on its draft guidance on the use of Orkambi, Symkevi and Kaftrio for the treatment of cystic fibrosis and continues to work with stakeholders to address the issues highlighted by the committee in the draft guidance. The Department encourages stakeholders such as patients and representative organisations to continue to engage in the NICE appraisal process.